Buy Ofev

Ofev

What is Ofev?

Ofev is a branded medication that contains the active ingredient nintedanib. It is supplied as 100 mg capsules (caps) and is prescribed in the United Kingdom under the oversight of the MHRA. Nintedanib belongs to a class of drugs known as tyrosine-kinase inhibitors and is used to slow the progression of certain chronic lung-fibrosis conditions.

How Ofev Works in the Body

Nintedanib blocks several receptor tyrosine kinases that play key roles in the formation of scar tissue (fibrosis) within the lungs. By inhibiting signals from vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors, the drug reduces the activation and proliferation of fibroblasts. This results in:

• Slower thickening of lung tissue
• Reduced decline in lung function
• Stabilisation of symptoms related to lung fibrosis

The onset of effect is gradual, with measurable benefits typically observed after several weeks of consistent dosing.

Conditions Treated by Ofev

Ofev is approved in the UK for the following indications:

• Idiopathic Pulmonary Fibrosis (IPF) - a progressive, scarring lung disease without a known cause.
• Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) - lung fibrosis linked to systemic sclerosis.
• Other Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) - a broader group of fibrotic lung disorders that continue to worsen despite standard treatment.

These approvals are based on clinical trials demonstrating that nintedanib reduces the rate of decline in forced vital capacity (FVC), a key measure of lung function. Ofev is not approved for asthma or other obstructive airway diseases.

Off-Label and Investigational Applications

Current peer-reviewed evidence does not support routine off-label use of Ofev for asthma, chronic obstructive pulmonary disease (COPD), or other non-fibrotic respiratory conditions. Ongoing research is exploring its potential in other fibrotic diseases, but such uses remain investigational and should only be considered within a clinical trial setting.

Disclaimer: Off-label use of any medication must be overseen by a qualified healthcare professional, with individualized risk assessment.

Who Should (Not) Use Ofev?

Absolute Contraindications

• Known hypersensitivity to nintedanib or any capsule ingredient.
• Severe liver impairment (Child-Pugh class C).
• Pregnancy (risk of fetal harm) - Ofev is contraindicated.
• Breast-feeding (the drug is excreted in milk).

Relative Contraindications / Cautions

• Moderate liver disease (Child-Pugh A/B) - requires dose adjustment and close monitoring.
• History of bleeding disorders or concurrent use of strong anticoagulants.
• Renal impairment (dose may be adjusted in severe cases).
• Patients aged ≥ 75 years - monitor tolerability closely.

Special Populations

• Pregnancy & lactation: Women who are pregnant, planning pregnancy, or breastfeeding should not take Ofev.
• Elderly: Dose adjustments are not routinely required, but side-effect monitoring is essential.
• Pediatric use: Safety and efficacy have not been established in children; Ofev is not indicated for patients under 18 years.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Diarrhoea - often mild to moderate; staying hydrated and using over-the-counter antidiarrhoeals can help.
• Nausea and abdominal pain - usually improve with meals or dose timing adjustments.
• Reduced appetite - monitor nutritional intake.

Serious Adverse Events

• Liver enzyme elevations (ALT/AST) - may indicate hepatic injury; requires regular blood-test monitoring.
• Bleeding complications - caution when combined with anticoagulants or antiplatelet drugs.
• Severe infections - reported rarely; seek medical attention if fever or unexplained illness occurs.

Drug Interactions

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nintedanib exposure → consider dose reduction.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): decrease exposure → efficacy may be reduced.
• P-glycoprotein (P-gp) inhibitors (e.g., quinidine): may raise nintedanib levels.
• Anticoagulants (warfarin, direct oral anticoagulants): higher bleeding risk; monitor coagulation status.

Patients should provide a complete medication list-including over-the-counter drugs, supplements, and herbal products-to their healthcare provider before starting Ofev.

Food and Lifestyle Interactions

• Food: Ofev can be taken with or without food; however, taking it with a meal may lessen gastrointestinal upset.
• Alcohol: Moderate consumption is permissible, but excessive alcohol can worsen liver toxicity.
• Driving: No impairment expected, but severe diarrhoea or dizziness should be assessed before operating machinery.

How to Take Ofev

• Standard dosing: One 100 mg capsule taken orally twice daily (approximately 12 hours apart).
• Administration: Swallow the capsule whole with water; do not crush or chew.
• Missed dose: If a dose is missed and the next scheduled dose is soon, skip the missed dose-do not double-dose.
• Dose adjustments:
• Hepatic impairment (Child-Pugh A/B): Reduce to one capsule once daily; monitor liver function tests.
• Severe drug interactions: Dose may be reduced to one capsule once daily or held, depending on the interacting agent.
• Overdose: Symptoms may include severe diarrhoea, nausea, vomiting, and liver enzyme elevation. Seek emergency medical care; supportive treatment is the mainstay.
• Discontinuation: Stopping Ofev abruptly is acceptable, but patients should discuss tapering or monitoring plans with their clinician, especially if used for ongoing fibrosis management.

Monitoring and Follow-Up

• Liver function tests (ALT, AST, bilirubin): Baseline, then every 4 weeks for the first three months, and periodically thereafter.
• Complete blood count: Periodic monitoring to detect rare hematologic abnormalities.
• Pulmonary function (FVC): Every 3-6 months to assess disease progression.
• Clinical review: Patients should report persistent diarrhoea, unexplained weight loss, or signs of bleeding promptly.

Storage and Handling

• Store Ofev capsules at room temperature (15-30 °C), protected from moisture and direct light.
• Keep the container tightly closed and out of reach of children.
• Do not use after the expiration date printed on the packaging.
• Dispose of unused medication according to local pharmacy take-back programs or MHRA guidelines.

Medication-Specific Glossary

Tyrosine-Kinase Inhibitor (TKI)

A drug class that blocks enzymes (tyrosine kinases) involved in cell signalling pathways, thereby reducing abnormal cell growth and tissue scarring.

Fibrosis

The formation of excess fibrous connective tissue, leading to stiffening and loss of function in organs such as the lungs.

Interstitial Lung Disease (ILD)

A heterogeneous group of lung disorders characterized by inflammation and fibrosis of the interstitium (the tissue surrounding the air sacs).

Forced Vital Capacity (FVC)

The maximum amount of air a person can forcefully exhale after a full inhalation; a key metric for tracking lung function in fibrotic diseases.

Medical Disclaimer

This article provides educational information about Ofev and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.